SG160430A1 - Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods - Google Patents

Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods

Info

Publication number
SG160430A1
SG160430A1 SG201001981-8A SG2010019818A SG160430A1 SG 160430 A1 SG160430 A1 SG 160430A1 SG 2010019818 A SG2010019818 A SG 2010019818A SG 160430 A1 SG160430 A1 SG 160430A1
Authority
SG
Singapore
Prior art keywords
immune modulators
preparations
compositions
compositions including
immune
Prior art date
Application number
SG201001981-8A
Other languages
English (en)
Inventor
David Lisonbee
Calvin W Mccausland
Richard H Bennett
Brent M Vaughan
Shane M Lefler
Original Assignee
4Life Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Life Res Llc filed Critical 4Life Res Llc
Publication of SG160430A1 publication Critical patent/SG160430A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
SG201001981-8A 2006-09-29 2007-09-19 Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods SG160430A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84834806P 2006-09-29 2006-09-29
US11/855,944 US10471100B2 (en) 2006-09-29 2007-09-14 Nanofraction immune modulators, preparations and compositions including the same, and associated methods

Publications (1)

Publication Number Publication Date
SG160430A1 true SG160430A1 (en) 2010-04-29

Family

ID=39261440

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001981-8A SG160430A1 (en) 2006-09-29 2007-09-19 Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods

Country Status (15)

Country Link
US (2) US10471100B2 (fr)
EP (1) EP2068913B1 (fr)
JP (3) JP5592651B2 (fr)
CN (1) CN101553247B (fr)
AU (1) AU2007305076B2 (fr)
CO (1) CO6220833A2 (fr)
EC (1) ECSP099296A (fr)
ES (1) ES2658107T3 (fr)
HK (1) HK1138181A1 (fr)
MX (1) MX2009003324A (fr)
MY (2) MY158857A (fr)
RU (2) RU2518341C2 (fr)
SG (1) SG160430A1 (fr)
TW (1) TWI449530B (fr)
WO (1) WO2008042604A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197894B2 (en) 2006-09-29 2021-12-14 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6866868B1 (en) * 2003-09-15 2005-03-15 4Life Research, Lc Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
AU2006242106B2 (en) * 2005-05-02 2013-01-17 4Life Patents, Llc Transfer factor preparations and associated methods
US9028882B2 (en) 2005-05-02 2015-05-12 4Life Patents, Llc Nutraceutical gels
TW201105966A (en) * 2009-05-05 2011-02-16 4Life Patents Llc Methods and systems for assaying, maintaining, and enhancing the activity of the immune system of a subject
EP3424531A1 (fr) 2010-11-23 2019-01-09 Pantheryx, Inc. Compositions et procédés de traitement dans des applications cliniques à large spectre, non différenciées ou mélangées
CN102172360B (zh) * 2011-02-17 2013-04-24 南京大学 一种牛初乳提取物及其提取方法和应用
WO2013039373A2 (fr) * 2011-09-13 2013-03-21 Zepeda Lopez Hector Manuel Extrait dialysé de leucocytes issu de rate de requin utilisé pour obtenir un facteur de transfert potentialisé, et procédé d'extraction, d'essai et de comptage de ce dernier
WO2013039374A2 (fr) * 2011-09-15 2013-03-21 Zepeda Lopez Hector Manuel Procédé d'extraction, d'essai et de comptage d'extrait dialysé de leucocytes provenant de rate de requin, pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant que traitement contre la maladie connue sous le nom de vitiligo
WO2013043032A2 (fr) * 2011-09-19 2013-03-28 Zepeda Lopez Hector Manuel Extrait dialysé de leucocytes issu de rate de requin utilisé pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant qu'immunomodulateur et procédé d'extraction, d'essai et de comptage de ce dernier
WO2013043033A2 (fr) * 2011-09-19 2013-03-28 Zepeda Lopez Hector Manuel Procédé d'extraction et d'essai d'extrait dialiysé de leucocytes provenant de rate de requin, pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant qu'adjuvant potentialisateur de vaccins viraux
WO2013058640A2 (fr) * 2011-10-20 2013-04-25 Zepeda Lopez Hector Manuel Procédé d'extraction, d'essai et de comptage d'extrait dialysé de leucocytes provenant de rate de requin, pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant que traitement contre la maladie connue sous le nom d'asthme
MX338863B (es) * 2011-12-16 2016-05-01 Inst Politecnico Nacional Metodo de obtencion de extracto dializable de leucocitos.
WO2015054694A2 (fr) 2013-10-13 2015-04-16 4Life Patents, Llc Compositions thérapeutiques et procédés de gestion des contraintes physiologiques et du vieillissement
KR101597540B1 (ko) * 2014-01-22 2016-02-29 건국대학교 산학협력단 난황 추출물을 유효성분으로 함유하는 면역증강용 조성물
WO2018232313A2 (fr) * 2017-06-15 2018-12-20 Miradx Biomarqueurs pour prédire une réponse tumorale à une immunothérapie et la toxicité d'une immunothérapie
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402938A (en) * 1980-05-29 1983-09-06 Impro Products, Inc. Food and the method of extracting the same from colostrum and milk
US4816563A (en) * 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
JPS60208919A (ja) * 1983-11-25 1985-10-21 アムトロン・インコ−ポレイテツド トランスフア−フアクタ−を初乳から得る方法、こうして得られたトランスフア−フアクタ−及びその使用
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
JP4127724B2 (ja) * 1996-03-26 2008-07-30 サイレックス インコーポレーテッド リンパ球機能の測定方法
NZ504132A (en) 1996-03-26 2002-03-28 Dcv Inc Anti-inflammatory composition from avian eggs, method of isolation and use in treating and preventing inflammation
US7169571B2 (en) * 1997-09-12 2007-01-30 Cylex, Inc. Methods for measurement of lymphocyte function
CZ287956B6 (cs) * 1997-11-04 2001-03-14 Medipharm Cz, S. R. O. Perorální přípravek k prevenci a léčbě parvovirózy psů
US20020044942A1 (en) * 2000-09-18 2002-04-18 Chisolm Biological Laboratory, Llc Transfer factor composition and process for producing same
US6468534B1 (en) 2000-09-21 2002-10-22 4Life Research, Lc Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use
WO2002038164A1 (fr) 2000-11-08 2002-05-16 Lorus Therapeutics Inc. Preparation combinee d'un modificateur de reponse biologique et d'un agent anticancereux et utilisations de cette derniere
US20030003117A1 (en) * 2001-06-18 2003-01-02 Michael Marenick Hydrolyzed whole egg products & related methods
KR20040105710A (ko) * 2002-02-11 2004-12-16 아르키온 라이프 사이언씨즈 엘엘씨 정제된 사이토킨 억제인자
US20040005327A1 (en) * 2002-05-16 2004-01-08 Subramanian Iyer Immune T-cell stimulation
WO2004041071A2 (fr) 2002-11-04 2004-05-21 4Life Research, Lc Compositions, systemes et methodes permettant de focaliser une reponse immunitaire a mediation cellulaire
CN1460522A (zh) 2003-06-16 2003-12-10 郭占军 预防和治疗疾病的蛋黄抗体组合物及其制备方法
US6866868B1 (en) * 2003-09-15 2005-03-15 4Life Research, Lc Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
US10471100B2 (en) 2006-09-29 2019-11-12 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods
CN100502674C (zh) 2005-10-13 2009-06-24 复旦大学 一种牛初乳和香菇提取物组合物及其制备方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197894B2 (en) 2006-09-29 2021-12-14 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods

Also Published As

Publication number Publication date
JP2010504988A (ja) 2010-02-18
US20080081076A1 (en) 2008-04-03
CN101553247A (zh) 2009-10-07
US10471100B2 (en) 2019-11-12
HK1138181A1 (zh) 2010-08-20
US11197894B2 (en) 2021-12-14
ECSP099296A (es) 2010-02-26
RU2014102562A (ru) 2015-08-20
CO6220833A2 (es) 2010-11-19
EP2068913A4 (fr) 2009-12-02
CN101553247B (zh) 2015-08-19
RU2619555C2 (ru) 2017-05-16
ES2658107T3 (es) 2018-03-08
EP2068913B1 (fr) 2017-11-01
MY158857A (en) 2016-11-15
TWI449530B (zh) 2014-08-21
EP2068913A2 (fr) 2009-06-17
WO2008042604A3 (fr) 2008-11-06
RU2009116274A (ru) 2010-11-10
JP2014129413A (ja) 2014-07-10
MX2009003324A (es) 2009-06-30
AU2007305076B2 (en) 2011-04-28
JP2016196491A (ja) 2016-11-24
JP6401744B2 (ja) 2018-10-10
RU2518341C2 (ru) 2014-06-10
US20200069737A1 (en) 2020-03-05
JP5592651B2 (ja) 2014-09-17
WO2008042604A2 (fr) 2008-04-10
MY188915A (en) 2022-01-13
AU2007305076A1 (en) 2008-04-10
TW200831116A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
SG160430A1 (en) Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods
BRPI0503828A (pt) formulações contendo pó, aquosas, lìquidas, não alcoólicas
WO2009061681A3 (fr) Antagonistes de récepteurs pgd2
TN2011000161A1 (en) Fgf21 mutants and uses thereof
WO2006101955A3 (fr) Compositions de revetement liquide
MY152721A (en) Fgf21 mutants and uses thereof
MY156542A (en) Fgf21 mutants and uses thereof
WO2007041511A3 (fr) Kinase des progeniteurs hematopoietiques 1 destinee a la modulation d'une reponse immune
ATE480223T1 (de) Kosmetische zusammensetzungen mit blockcopolymeren und entsprechendes system von dauerhaften kosmetikprodukten
WO2006053010A3 (fr) Utilisation d'antioxydants dans la modulation genique
WO2006060182A3 (fr) Peptides hk hautement ramifies utilises en tant que porteurs efficaces de petits arn interferents
WO2010025421A3 (fr) Modulateurs de myc, procédés d'utilisation de ces derniers et procédés d'identification d'agents modulant myc
NO20065051L (no) Bazedoksifenacetat faste dispersjonsfomuleringer
WO2008073174A3 (fr) Thérapie antimicrobienne
MX2010002028A (es) Metodos y composiciones para modular celulas t.
MX2010013913A (es) 5-fenil-isoxazol-3-carboxamidas que modulan hsp90 con actividad antitumoral.
NZ596813A (en) Drug delivery systems
WO2007041364A3 (fr) Methodes et compositions permettant de moduler la tolerance immunitaire
WO2009017719A8 (fr) Modulateurs du récepteur ccr9 et leurs procédés d'utilisation
WO2009040512A3 (fr) Modulation de rsk
WO2008027855A3 (fr) Compositions et procédés pour moduler la signalisation de mtor
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
WO2007002093A3 (fr) Formulations d'ansamycine et leurs procedes d'utilisation
WO2006031786A3 (fr) Compositions de proteine a et procedes d'utilisation
WO2003083057A3 (fr) Adipocytes et leurs utilisations